Home
Live Updates
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC : comparemela.com
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC
SUZHOU, China, June 2, 2024 /PRNewswire/ — CStone Pharmaceuticals (HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and…
Related Keywords
China ,
Switzerland ,
United Kingdom ,
Suzhou ,
Jiangsu ,
Jason Yang ,
European Medicines Agency ,
Regulatory Agency ,
Committee For Medicinal Products Human Use ,
Cstone Pharmaceuticals ,
European Commission ,
Drug Administration ,
National Medical Products Administration ,
Central Eastern Europe ,
Medicinal Products ,
Human Use ,
Executive Director ,
Lancet Oncology ,
Nature Cancer ,
Combined Positive Score ,
Transl Lung Cancer Res ,
comparemela.com © 2020. All Rights Reserved.